Hoi-Shen Radcliffe

769 total citations
10 papers, 477 citations indexed

About

Hoi-Shen Radcliffe is a scholar working on Oncology, Molecular Biology and Orthopedics and Sports Medicine. According to data from OpenAlex, Hoi-Shen Radcliffe has authored 10 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Orthopedics and Sports Medicine. Recurrent topics in Hoi-Shen Radcliffe's work include CAR-T cell therapy research (3 papers), Cutaneous Melanoma Detection and Management (3 papers) and Bone health and osteoporosis research (3 papers). Hoi-Shen Radcliffe is often cited by papers focused on CAR-T cell therapy research (3 papers), Cutaneous Melanoma Detection and Management (3 papers) and Bone health and osteoporosis research (3 papers). Hoi-Shen Radcliffe collaborates with scholars based in United Kingdom, United States and Switzerland. Hoi-Shen Radcliffe's co-authors include Christian Roux, Adolfo Díez‐Pérez, Cyrus Cooper, Susan Shepherd, Nick Freemantle, Matthew Gitlin, Thomas Fuerst, Michael R. McClung, Cesar Libanati and José Zanchetta and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hoi-Shen Radcliffe

10 papers receiving 467 citations

Peers

Hoi-Shen Radcliffe
Kam Newman United States
Yoshiyasu Ogata Japan
Abdul Hameed Pakistan
Léonardo Magro France
Christine Delprat France
Jochen Sieper Germany
J Craig United Kingdom
Folashade Otegbeye United States
Simon Hirschmann Germany
Michael Carlson United States
Kam Newman United States
Hoi-Shen Radcliffe
Citations per year, relative to Hoi-Shen Radcliffe Hoi-Shen Radcliffe (= 1×) peers Kam Newman

Countries citing papers authored by Hoi-Shen Radcliffe

Since Specialization
Citations

This map shows the geographic impact of Hoi-Shen Radcliffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hoi-Shen Radcliffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hoi-Shen Radcliffe more than expected).

Fields of papers citing papers by Hoi-Shen Radcliffe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hoi-Shen Radcliffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hoi-Shen Radcliffe. The network helps show where Hoi-Shen Radcliffe may publish in the future.

Co-authorship network of co-authors of Hoi-Shen Radcliffe

This figure shows the co-authorship network connecting the top 25 collaborators of Hoi-Shen Radcliffe. A scholar is included among the top collaborators of Hoi-Shen Radcliffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hoi-Shen Radcliffe. Hoi-Shen Radcliffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Dummer, Reinhard, David Gyorki, John Hyngstrom, et al.. (2021). Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial. Nature Medicine. 27(10). 1789–1796. 89 indexed citations
2.
3.
Harrington, Kevin J., Anthony Kong, Nicolas Mach, et al.. (2020). Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research. 26(19). 5153–5161. 83 indexed citations
4.
Dummer, Reinhard, David Gyorki, John Hyngstrom, et al.. (2020). 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. SHILAP Revista de lepidopterología. A263.1–A263. 9 indexed citations
5.
Middleton, Mark R., Kevin J. Harrington, Merrick Ross, et al.. (2019). Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study. Annals of Oncology. 30. v547–v548. 1 indexed citations
6.
7.
Moos, Roger von, Giorgio V. Scagliotti, H.P. Sleeboom, et al.. (2016). Symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid. Annals of Oncology. 27. vi507–vi507. 3 indexed citations
8.
Genant, Harry K., Cesar Libanati, Klaus Engelke, et al.. (2013). Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone. 56(2). 482–488. 49 indexed citations
9.
Keaveny, Tony M., Michael R. McClung, Harry K. Genant, et al.. (2013). Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab. Journal of Bone and Mineral Research. 29(1). 158–165. 78 indexed citations
10.
Freemantle, Nick, Cyrus Cooper, Adolfo Díez‐Pérez, et al.. (2012). Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporosis International. 24(1). 209–217. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kam Newman Breakdown of academic impact, for papers by Yoshiyasu Ogata Breakdown of academic impact, for papers by Abdul Hameed Breakdown of academic impact, for papers by Léonardo Magro Breakdown of academic impact, for papers by Christine Delprat Breakdown of academic impact, for papers by Jochen Sieper Breakdown of academic impact, for papers by J Craig Breakdown of academic impact, for papers by Folashade Otegbeye Breakdown of academic impact, for papers by Simon Hirschmann Breakdown of academic impact, for papers by Michael Carlson
Rankless by CCL
2026